John Mark O'Mahony - Jan 26, 2024 Form 4 Insider Report for LEAP THERAPEUTICS, INC. (LPTX)

Role
Chief Manufacturing Officer
Signature
/s/ Douglas E. Onsi, as attorney-in-fact for John Mark O'Mahony
Stock symbol
LPTX
Transactions as of
Jan 26, 2024
Transactions value $
$0
Form type
4
Date filed
1/30/2024, 08:41 PM
Previous filing
Aug 25, 2023
Next filing
Jan 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LPTX Common Stock Options Exercise +5K 5K Jan 26, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LPTX Restricted Stock Units Options Exercise $0 -5K -100% $0.00* 0 Jan 26, 2024 Common Stock 5K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units convert into common stock on a one-for-one basis.
F2 The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.
F3 On January 26, 2021, the reporting person was granted 5,000 Restricted Stock Units, vesting on January 26, 2024 or upon a change of control, whichever is earlier, provided that the grantee continues to be employed by, or provides service to the Company from the grant date to the vesting date of the Restricted Stock Units. At such time as the Restricted Stock Units vest, one share of Common Stock shall be issued automatically in settlement of each Restricted Stock Unit.